CorMedix (CRMD) Assets Average (2011 - 2026)
CorMedix (CRMD) posted Assets Average of $788.5 million for Q4 2025, up 57.16% sequentially from $501.7 million in Q3 2025, and up 702.82% YoY from $98.2 million in Q4 2024.
CorMedix (CRMD) Assets Average (2011 - 2026) Analysis & Trends
CorMedix has reported Assets Average for 13 years, with the latest figure at $788.5 million in Q4 2025.
- Quarterly Assets Average rose 702.82% year-over-year to $788.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $788.5 million (up 702.82% YoY) and the FY2025 annual result came in at $472.5 million, up 370.36% from the prior year.
- Assets Average advanced to $788.5 million in Q4 2025 per CRMD's latest filing, from $501.7 million in the prior quarter.
- Over five years, Assets Average peaked at $788.5 million in Q4 2025 and troughed at $58.1 million in Q2 2023.
- A 5-year average of $138.4 million and a median of $73.2 million in 2021 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average slipped 19.64% in 2022, then surged 702.82% in 2025.
- Over 5 years, Assets Average stood at $72.2 million in 2021, then dropped by 14.01% to $62.1 million in 2022, then jumped by 39.78% to $86.7 million in 2023, then rose by 13.22% to $98.2 million in 2024, then soared by 702.82% to $788.5 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $788.5 million, $501.7 million, and $201.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 865.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 865.10 Mn |
| Dec 31, 2025 | 788.50 Mn |
| Sep 30, 2025 | 501.73 Mn |
| Jun 30, 2025 | 201.09 Mn |
| Mar 31, 2025 | 134.21 Mn |
| Dec 31, 2024 | 98.22 Mn |
| Sep 30, 2024 | 67.66 Mn |
| Jun 30, 2024 | 62.88 Mn |
| Mar 31, 2024 | 75.04 Mn |
| Dec 31, 2023 | 86.74 Mn |
| Sep 30, 2023 | 74.23 Mn |
| Jun 30, 2023 | 58.13 Mn |
| Mar 31, 2023 | 60.64 Mn |
| Dec 31, 2022 | 62.06 Mn |
| Sep 30, 2022 | 64.91 Mn |
| Jun 30, 2022 | 66.34 Mn |
| Mar 31, 2022 | 66.94 Mn |
| Dec 31, 2021 | 72.17 Mn |
| Sep 30, 2021 | 78.12 Mn |
| Jun 30, 2021 | 82.56 Mn |